Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Please join us for an ECHO webinar on Tuesday Apr 20, 2021 (11 am – 12 pm) featuring Dr. Margaret Magdesian (CEO and Founder, Ananda Devices). Dr. Magdesian’s presentation entitled, “Scientific entrepreneurship and the need for new tools to achieve the UN sustainable development goals”, will feature an overview of Ananda Devices, its technologies and the story behind its success.
Ananda Devices is a certified Women Owned SME offering products and services for more efficient growth of human nervous system-on-a-chip. Their products enable pharmaceutical, vaccine and cosmetic industries to perform drug screening, toxicity and efficacy testing up to 50x faster and 90% more cost-effective than current technologies. Their products facilitate automation of biological tests on models of human brain, spinal cord and innervated tissue.
Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZAsfuuorz0iH9ybWINFqFA2NMI7ImUNzFQL
After registering, you will receive a confirmation email containing information about joining the webinar.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).